| Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs A Haslam, V Prasad JAMA network open 2 (5), e192535-e192535, 2019 | 857 | 2019 |
| Research and development spending to bring a single cancer drug to market and revenues after approval V Prasad, S Mailankody JAMA internal medicine 177 (11), 1569-1575, 2017 | 440 | 2017 |
| A Decade of Reversal: An Analysis of 146 Contradicted Medical Practices V Prasad, A Vandross, C Toomey, M Cheung, J Rho, S Quinn, SJ Chacko, ... Mayo Clinic Proceedings, 2013 | 419 | 2013 |
| Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals C Kim, V Prasad JAMA Internal Medicine 175 (12), 1992-1994, 2015 | 377 | 2015 |
| Evidence-based de-implementation for contradicted, unproven, and aspiring healthcare practices V Prasad, JPA Ioannidis Implementation Science 9 (1), 1-5, 2014 | 341 | 2014 |
| The high price of anticancer drugs: origins, implications, barriers, solutions V Prasad, K De Jesús, S Mailankody Nature reviews Clinical oncology 14 (6), 381-390, 2017 | 340 | 2017 |
| The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses V Prasad, C Kim, M Burotto, A Vandross JAMA internal medicine 175 (8), 1389-1398, 2015 | 327 | 2015 |
| The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses V Prasad, C Kim, M Burotto, A Vandross JAMA internal medicine 175 (8), 1389-1398, 2015 | 327 | 2015 |
| Perspective: the precision-oncology illusion V Prasad Nature 537 (7619), S63-S63, 2016 | 322 | 2016 |
| Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology J Marquart, EY Chen, V Prasad JAMA oncology 4 (8), 1093-1098, 2018 | 312 | 2018 |
| Five years of cancer drug approvals: innovation, efficacy, and costs S Mailankody, V Prasad JAMA oncology 1 (4), 539-540, 2015 | 304 | 2015 |
| Reversals of Established Medical Practices: Evidence to Abandon Ship V Prasad, A Cifu, JPA Ioannidis JAMA 307 (1), 37-38, 2012 | 243 | 2012 |
| Precision oncology: origins, optimism, and potential V Prasad, T Fojo, M Brada The Lancet Oncology 17 (2), e81-e86, 2016 | 230 | 2016 |
| Prespecified Falsification End PointsCan They Validate True Observational Associations? Prespecified Falsification End Points V Prasad, AB Jena JAMA 309 (3), 241-242, 2013 | 224 | 2013 |
| Tisagenlecleucel—the first approved CAR-T-cell therapy: implications for payers and policy makers V Prasad Nature Reviews Clinical Oncology 15 (1), 11-12, 2018 | 221 | 2018 |
| Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused? R Kemp, V Prasad BMC medicine 15 (1), 1-7, 2017 | 216 | 2017 |
| Ending medical reversal: improving outcomes, saving lives VK Prasad, AS Cifu Johns Hopkins University Press, 2019 | 161 | 2019 |
| Why cancer screening has never been shown to “save lives”—and what we can do about it V Prasad, J Lenzer, DH Newman Bmj 352, 2016 | 156 | 2016 |
| The frequency of medical reversal V Prasad, V Gall, A Cifu Archives of internal medicine 171 (18), 1675-1676, 2011 | 147 | 2011 |
| A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology A Haslam, SP Hey, J Gill, V Prasad European Journal of Cancer 106, 196-211, 2019 | 141 | 2019 |
Alyson HaslamUniversity of California San Francisco在 ucsf.edu 的电子邮件经过验证
